Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE) is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.
Highlights:
• New test integrates the patented and proprietary GeneType platform for both Breast and Ovarian Cancer.
• GTG’s unique approach “appends” the detection of the 13 major “actionable” breast and ovarian cancer
susceptibility genes to the GeneType test platform.
• Results in a higher classification rate of women at elevated risk of breast and ovarian cancer than traditional
clinical tools by assessing breast and ovarian cancer susceptibility from both rare and common genetic variants
in addition to other known clinical risk factors associated with the development of both diseases.
• Advances the goal of providing population-based genetic screening for Breast and Ovarian cancer where up to
85% of cancers diagnosed do not have hereditary or family history1
.
• The new test platform addresses those women over 30 years of age in the general population that are at higher
risk of developing breast and/or ovarian cancer, not just from rare genetic mutations.
• The comprehensive risk assessment test will be clinically validated and have appropriate regulatory approval.
• This test will be launched via our Business to Business (‘B2B’) and Consumer Initiated Testing (‘CIT’) channels
in the United States.
• The Comprehensive Risk Test will be showcased at the BRCA 2023 Symposium in Montreal in early May.
